JAK2 - Janus kinase 2 Gene
Species: Macaca mulatta
Gene Type: protein coding
Gene ID: 694184
About JAK2
Primary_assembly 15: 78,701,446-78,857,180 reverse strand.Mmul_10:CM014350.1
This gene has 2 transcripts (splice variants), 265 orthologues and 32 paralogues.
JAK2 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001265901.2 | NP_001252830.1 | tyrosine-protein kinase JAK2 |
JAK2 Protein Structure
FERM_F1
FERM_F1: pfam18379 (38 - 133)
FERM_F2
FERM_F2: pfam18377 (142 - 260)
FERM_C_JAK2
FERM_C_JAK2: cd13333 (265 - 385)
SH2_Jak2
SH2_Jak2: cd10379 (385 - 481)
PTK_Jak2_rpt1
PTK_Jak2_rpt1: cd05078 (544 - 805)
PTKc_Jak2_rpt2
PTKc_Jak2_rpt2: cd14205 (843 - 1126)
- 0
- 200
- 400
- 600
- 800
- 1000
- 1132 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
tyrosine-protein kinase JAK2 |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(25)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-50856 | Ruxolitinib | Inhibitor | 99.99% | Yes |
| HY-40354 | Tofacitinib | Inhibitor | 99.99% | Yes |
| HY-19569 | Upadacitinib | Inhibitor | 99.98% | Yes |
| HY-15315 | Baricitinib | Inhibitor | 99.97% | Yes |
| HY-10409 | Fedratinib | Inhibitor | 99.87% | Yes |
| HY-50858 | Ruxolitinib phosphate | Inhibitor | 99.97% | Yes |
| HY-40354A | Tofacitinib citrate | Inhibitor | 99.94% | Yes |
| HY-16379 | Pacritinib | Inhibitor | 99.93% | Yes |
| HY-107429 | Abrocitinib | Inhibitor | 99.26% | Unkown |
| HY-18300 | Filgotinib | Inhibitor | 99.77% | Yes |
| HY-19568 | Peficitinib | Inhibitor | 99.43% | Yes |
| HY-15315A | Baricitinib phosphate | Inhibitor | 99.97% | Yes |
| HY-10409A | Fedratinib hydrochloride hydrate | Inhibitor | 99.92% | Yes |
| HY-109053 | Delgocitinib | Inhibitor | 99.61% | Unkown |
| HY-13577 | Oclacitinib | Inhibitor | 99.03% | Unkown |
| HY-50867 | Lestaurtinib | Inhibitor | 99.66% | Unkown |
| HY-13577A | Oclacitinib monomaleate | Inhibitor | 99.87% | Unkown |
| HY-15728 | Radotinib | Inhibitor | 99.19% | Yes |
| HY-50856S | Deuruxolitinib | Inhibitor | 99.18% | Unkown |
| HY-18300A | Filgotinib maleate | Inhibitor | 99.88% | Yes |
| HY-50859 | Ruxolitinib sulfate | Inhibitor | / | Unkown |
| HY-19569A | Upadacitinib tartrate tetrahydrate | Inhibitor | / | Unkown |
| HY-19568A | Peficitinib hydrobromide | Inhibitor | / | Unkown |
| HY-16379A | Pacritinib hydrochloride | Inhibitor | / | Unkown |
| HY-19568B | Peficitinib hydrochloride | Inhibitor | / | Unkown |
Clinical Phase
Bioactive Molecules
(33)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-155785 | MTP | Inhibitor | / | Phase 4 |
| HY-10961 | Momelotinib | Inhibitor | 98.93% | Phase 3 |
| HY-112708 | Brepocitinib | Inhibitor | 99.97% | Phase 3 |
| HY-50514 | AT9283 | Inhibitor | 99.67% | Phase 3 |
| HY-15999 | Cerdulatinib | Inhibitor | 99.06% | Phase 3 |
| HY-12469 | Decernotinib | Inhibitor | 99.91% | Phase 3 |
| HY-10962 | Momelotinib sulfate | Inhibitor | 98.63% | Phase 3 |
| HY-112724 | Ivarmacitinib | Inhibitor | 99.62% | Phase 3 |
| HY-13775 | XL019 | Inhibitor | 99.65% | Phase 3 |
| HY-15999A | Cerdulatinib hydrochloride | Inhibitor | 98.96% | Phase 3 |
| HY-109038 | Mocravimod | Activator | 98.39% | Phase 3 |
| HY-10963 | Momelotinib mesylate | Inhibitor | / | Phase 3 |
| HY-15312 | WP1066 | Inhibitor | 99.53% | Phase 2 |
| HY-10193 | AZD-1480 | Inhibitor | 99.74% | Phase 2 |
| HY-13034 | Gandotinib | Inhibitor | 99.86% | Phase 2 |
| HY-130247 | Flonoltinib | Inhibitor | 99.48% | Phase 2 |
| HY-15270 | BMS-911543 | Inhibitor | 98.23% | Phase 2 |
| HY-19631A | Ilginatinib | Inhibitor | 99.81% | Phase 2 |
| HY-156961 | Cadefrecitinib | Inhibitor | 99.81% | Phase 2 |
| HY-112708A | Brepocitinib P-Tosylate | Inhibitor | 99.99% | Phase 2 |
| HY-15163 | Zotiraciclib | Inhibitor | 99.88% | Phase 2 |
| HY-109179 | Itacnosertib | Inhibitor | 99.06% | Phase 2 |
| HY-19631B | Ilginatinib hydrochloride | Inhibitor | 98.92% | Phase 2 |
| HY-19631 | Ilginatinib maleate | Inhibitor | 99.33% | Phase 2 |
| HY-130247A | Flonoltinib TFA | Inhibitor | 98.94% | Phase 2 |
| HY-10058 | AT9283 lactic acid | Inhibitor | / | Phase 2 |
| HY-15504 | RGB-286638 | Inhibitor | 99.67% | Phase 1 |
| HY-101024 | PF-06263276 | Inhibitor | ≥99.0% | Phase 1 |
| HY-15504A | RGB-286638 free base | Inhibitor | 98.09% | Phase 1 |
| HY-112809 | GSK2646264 | Inhibitor | 99.74% | Phase 1 |
| HY-124067 | EC-70124 | Inhibitor | / | Phase 1 |
| HY-16449 | SB1578 | Inhibitor | / | Phase 1 |
| HY-16021 | AC-430 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(133)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-148748 | Butyzamide | Activator | 99.83% | Unkown |
| HY-18960 | CHZ868 | Inhibitor | 98.69% | Unkown |
| HY-N1405 | Cucurbitacin I | Inhibitor | 99.60% | Unkown |
| HY-14435 | Pyridone 6 | Inhibitor | 98.20% | Unkown |
| HY-15480 | NSC 42834 | Inhibitor | 96.85% | Unkown |
| HY-15166 | (E/Z)-Zotiraciclib | Inhibitor | 99.96% | Unkown |
| HY-15343 | CEP-33779 | Inhibitor | 99.23% | Unkown |
| HY-145551 | Atinvicitinib | Inhibitor | 98.62% | Unkown |
| HY-145696 | SJ10542 | Inhibitor | 99.32% | Unkown |
| HY-151902 | SJ988497 | Degrader | 99.03% | Unkown |
| HY-N0885 | Telocinobufagin | Inhibitor | 99.93% | Unkown |
| HY-N2963 | Broussonin E | Activator | 98.11% | Unkown |
| HY-113573 | Protosappanin A | 99.95% | Unkown | |
| HY-10411 | AZ960 | Inhibitor | 97.08% | Unkown |
| HY-14722 | NVP-BSK805 | Inhibitor | 99.30% | Unkown |
| HY-10410 | TG101209 | Inhibitor | 98.81% | Unkown |
| HY-100895 | SAR-20347 | Inhibitor | 97.27% | Unkown |
| HY-108264 | TCS 21311 | Inhibitor | 99.49% | Unkown |
| HY-137756 | JAK2-IN-6 | Inhibitor | 97.07% | Unkown |
| HY-113787 | (R)-9b | Inhibitor | 99.51% | Unkown |
| HY-15166A | (E/Z)-Zotiraciclib hydrochloride | Inhibitor | 99.90% | Unkown |
| HY-N1356 | Reticuline | Inhibitor | 98.89% | Unkown |
| HY-N0918 | Desmethoxyyangonin | Inhibitor | 99.00% | Unkown |
| HY-151262 | JAK-IN-23 | Inhibitor | 98.88% | Unkown |
| HY-146186 | JAK2 JH2 binder-1 | Modulator | 95.40% | Unkown |
| HY-153701S | Envudeucitinibum | Inhibitor | 99.56% | Unkown |
| HY-115452 | G5-7 | Inhibitor | 98.45% | Unkown |
| HY-14722A | NVP-BSK805 dihydrochloride | Inhibitor | 99.36% | Unkown |
| HY-19544 | JAK3-IN-1 | Inhibitor | 99.31% | Unkown |
| HY-15166B | (E/Z)-Zotiraciclib citrate | Inhibitor | 99.83% | Unkown |
| HY-131906 | JAK2-IN-7 | Inhibitor | 98.31% | Unkown |
| HY-124858 | SC99 | Inhibitor | 98.90% | Unkown |
| HY-N3239 | Mulberrofuran G | Inhibitor | 97.86% | Unkown |
| HY-150720 | TYK2-IN-12 | Inhibitor | 98.81% | Unkown |
| HY-109179A | Itacnosertib hydrochloride | Inhibitor | 99.43% | Unkown |
| HY-179715 | PROTAC JAK1/2 degrader-1 | Degrader | 99.47% | Unkown |
| HY-169326S | JAK2-IN-11 | Inhibitor | 98.03% | Unkown |
| HY-147330B | SJ1008030 formic | Inhibitor | 98.91% | Unkown |
| HY-162248 | JAK1/2-IN-1 | Inhibitor | 98.36% | Unkown |
| HY-147330A | SJ1008030 TFA | Inhibitor | 98.12% | Unkown |
| HY-153440 | Methyl 6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate | Inhibitor | 98.01% | Unkown |
| HY-120469 | 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide | Inhibitor | 99.80% | Unkown |
| HY-139423 | JAK1-IN-8 | Inhibitor | 95.0% | Unkown |
| HY-143444 | JAK-IN-20 | Inhibitor | 99.63% | Unkown |
| HY-111750 | JAK-IN-3 | Inhibitor | 98.92% | Unkown |
| HY-N0143A | Phlorizin dihydrate | Antagonist | 99.51% | Unkown |
| HY-126141 | JAK/HDAC-IN-1 | Inhibitor | 98.63% | Unkown |
| HY-167846 | YLIU-4-105-1 | Inhibitor | 99.39% | Unkown |
| HY-124727 | ZT55 | Inhibitor | 99.51% | Unkown |
| HY-13961 | GLPG0634 analog | Inhibitor | 98.07% | Unkown |
| HY-164393 | ON044580 | Inhibitor | 99.11% | Unkown |
| HY-152080 | Blovacitinib | Inhibitor | 99.71% | Unkown |
| HY-100849 | JAK 3i | Inhibitor | 99.81% | Unkown |
| HY-116505 | JAK1-IN-4 | Inhibitor | 99.26% | Unkown |
| HY-120692 | Cyclanoline chloride | Inhibitor | 96.27% | Unkown |
| HY-179716 | JAK1/2 ligand 1 | Ligand | 99.91% | Unkown |
| HY-112391 | SD-1029 | Inhibitor | 88.8% | Unkown |
| HY-161684 | JAK2-IN-10 | Inhibitor | 97.97% | Unkown |
| HY-159536 | Frevecitinib | Inhibitor | 99.42% | Unkown |
| HY-125542 | DCZ3301 | Inhibitor | 99.73% | Unkown |
| HY-148060 | JAK-IN-21 | Inhibitor | 99.72% | Unkown |
| HY-170772 | Dual Cathepsin L/JAK-IN-1 | Inhibitor | 98.47% | Unkown |
| HY-161618 | MJ04 | Inhibitor | 98.08% | Unkown |
| HY-143884 | JAK2/TYK2-IN-1 | Inhibitor | 99.94% | Unkown |
| HY-107595 | SD-1008 | Inhibitor | 99.10% | Unkown |
| HY-181929 | RAI-20 | Inhibitor | 98.66% | Unkown |
| HY-14722C | NVP-BSK805 trihydrochloride | Inhibitor | / | Unkown |
| HY-184063 | Vexicitinib | Inhibitor | / | Unkown |
| HY-151259 | TK4b | Inhibitor | / | Unkown |
| HY-175684 | JAK2-IN-14 | Inhibitor | / | Unkown |
| HY-115541 | BRD4-IN-41 | / | Unkown | |
| HY-149296 | JAK1-IN-12 | Inhibitor | / | Unkown |
| HY-151256 | JAK-2/3-IN-2 | Inhibitor | / | Unkown |
| HY-177131 | Soficitinib | Inhibitor | / | Unkown |
| HY-156959 | Ovalicin | Inhibitor | / | Unkown |
| HY-151285 | JAK-2/3-IN-3 | Inhibitor | / | Unkown |
| HY-136734 | JAK2-IN-5 | Inhibitor | / | Unkown |
| HY-180766 | JAK2-IN-19 | Inhibitor | / | Unkown |
| HY-143885 | JAK1/TYK2-IN-3 | Inhibitor | / | Unkown |
| HY-183272 | PI3K/Akt/mTOR-IN-7 | Inhibitor | / | Unkown |
| HY-146727 | JAK3-IN-11 | Inhibitor | / | Unkown |
| HY-178936 | JAK2-IN-15 | Inhibitor | / | Unkown |
| HY-W064657 | Momelotinib dihydrochloride | Inhibitor | / | Unkown |
| HY-161967 | JAK2/FLT3-IN-3 | Inhibitor | / | Unkown |
| HY-149283 | JAK/HDAC-IN-2 | Inhibitor | / | Unkown |
| HY-177006 | JAK1/2-IN-2 | Inhibitor | / | Unkown |
| HY-144440 | JAK1-IN-9 | Inhibitor | / | Unkown |
| HY-18293 | NSC 33994 | Inhibitor | / | Unkown |
| HY-155951 | JAK3-IN-14 | Inhibitor | 99.32% | Unkown |
| HY-174428 | PROTAC JAK2 degrader-1 | Degrader | / | Unkown |
| HY-161139 | JAK1-IN-14 | Inhibitor | / | Unkown |
| HY-175611 | FLT3/JAK2/BRD4 ligand-1 | Ligand | / | Unkown |
| HY-179687 | JAK2-IN-18 | Inhibitor | / | Unkown |
| HY-178448 | EGFR-IN-178 | Inhibitor | / | Unkown |
| HY-147975 | JAK3-IN-12 | Inhibitor | / | Unkown |
| HY-178282 | JAK1-IN-19 | Inhibitor | / | Unkown |
| HY-108342 | PF-00956980 | Inhibitor | / | Unkown |
| HY-170723 | JAK-IN-39 | Inhibitor | / | Unkown |
| HY-162885 | YSY01A | Degrader | / | Unkown |
| HY-180274 | JAK1/2-IN-3 | Inhibitor | / | Unkown |
| HY-179428 | JAK2-IN-17 | Inhibitor | / | Unkown |
| HY-10652 | JAK-2/3-IN-1 | Inhibitor | / | Unkown |
| HY-182430 | NVP-BVB808 | Inhibitor | / | Unkown |
| HY-154994 | JAK-IN-30 | Inhibitor | / | Unkown |
| HY-151258 | TK4g | Inhibitor | / | Unkown |
| HY-181691 | JAK2-IN-20 | Inhibitor | / | Unkown |
| HY-147754 | JAK3/BTK-IN-6 | Inhibitor | / | Unkown |
| HY-175610 | PROTAC FLT3/JAK2/BRD4 Degrader-1 | Degrader | / | Unkown |
| HY-P10840 | Tkip | Inhibitor | 95.16% | Unkown |
| HY-117810 | JAK2-IN-1 | Inhibitor | / | Unkown |
| HY-174430 | WWQ-131 | Inhibitor | / | Unkown |
| HY-174999 | JAK3-IN-18 | Inhibitor | / | Unkown |
| HY-N14094 | Tubulosine | Inhibitor | / | Unkown |
| HY-183670 | JAK2-IN-21 | Inhibitor | / | Unkown |
| HY-129341 | WP1193 | Inhibitor | / | Unkown |
| HY-176793 | JAK1-IN-18 | Inhibitor | / | Unkown |
| HY-155746 | JAK2-IN-9 | Inhibitor | / | Unkown |
| HY-183370 | JAK2/STAT3-IN-2 | Inhibitor | / | Unkown |
| HY-N13352 | Bufothionine | Inhibitor | / | Unkown |
| HY-174988 | JAK2-IN-13 | Inhibitor | / | Unkown |
| HY-168269 | Tyk2-IN-20 | Inhibitor | / | Unkown |
| HY-160919 | JAK2-IN-16 | Inhibitor | / | Unkown |
| HY-123939 | JAK1/3-IN-1 | Inhibitor | / | Unkown |
| HY-123187 | AS2553627 | Inhibitor | / | Unkown |
| HY-162862 | JAK-IN-38 | Inhibitor | / | Unkown |
| HY-129679 | NMS-P953 | Inhibitor | / | Unkown |
| HY-119009 | TM-233 | Inhibitor | / | Unkown |
| HY-N8098 | Pulchinenoside E2 | Inhibitor | 99.28% | Unkown |
| HY-130247B | Flonoltinib monomaleate | Inhibitor | / | Unkown |
| HY-157121 | JAK-IN-34 | Inhibitor | / | Unkown |
| HY-183519 | AH057 | Inhibitor | / | Unkown |
| HY-124595 | MPT0B098 | / | Unkown | |
| HY-162862 | JAK-IN-38 | Inducer | / | Unkown |